Ocular Therapeutix Expands Its Board of Directors with the Appointment of Renowned Retinal Specialist Jeffrey S. Heier, M.D.

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jeffrey S. Heier, M.D., a prominent retinal specialist, has been elected to Ocular’s Board of Directors. Dr. Heier is a leading retinal clinical researcher of new treatments for diseases of the back of the eye, including macular degeneration, diabetic macular edem

Full Story →